Synergy between PPARgamma ligands and platinum-based drugs in cancer.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cancer Cell

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 17482130PMCID PMC2564847
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells

  2006cited by this paper
• Rosiglitazone ameliorates cisplatin-induced renal injury in mice.

  2006cited by this paper
• Hic-5 regulates an epithelial program mediated by PPARgamma.

  2005cited by this paper
• A Novel Peroxisome Proliferator-activated Receptor γ Isoform with Dominant Negative Activity Generated by Alternative Splicing*

  2005cited by this paper
• PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis.

  2004cited by this paper
• Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells

  2004cited by this paper
• Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate‐specific antigen level after radical prostatectomy and/or radiation therapy

  2004cited by this paper
• Peroxisome-proliferator-activated receptors and cancers: complex stories

  2004cited by this paper
• Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer.

  2004cited by this paper
• Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study

  2003cited by this paper
• AP-1: a double-edged sword in tumorigenesis

  2003cited by this paper
• Peroxisome proliferator-activated receptor gamma and cancers.

  2003cited by this paper
• Platinum drugs in the treatment of non-small-cell lung cancer

  2002cited by this paper
• Controversy: PPARgamma as a target for treatment of colorectal cancer.

  2002cited by this paper
• A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer.

  2002cited by this paper
• NF-kappaB in cancer: from innocent bystander to major culprit.

  2002cited by this paper
• APC-dependent suppression of colon carcinogenesis by PPARγ

  2002cited by this paper
• Cellular and molecular pharmacology of oxaliplatin.

  2002cited by this paper
• To arrest or not to G(2)-M Cell-cycle arrest : commentary re: A. K. Tyagi et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin. cancer res., 8: 3512-3519, 2002.

  2002cited by this paper
• Metallothionein: the multipurpose protein

  2002cited by this paper
• Emerging patterns and gene expression data.

  2001cited by this paper
• PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth.

  2001cited by this paper
• PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

  2001cited by this paper
• Is cisplatin-induced cell death always produced by apoptosis?

  2001cited by this paper
• Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs).

  2001cited by this paper
• Peroxisome proliferator-activated receptors in inflammation control.

  2001cited by this paper
• Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

  2000cited by this paper
• Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.

  2000cited by this paper
• Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer.

  2000cited by this paper
• PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro.

  1999cited by this paper
• Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase.

  1999cited by this paper
• PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance.

  1999cited by this paper
• Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).

  1999cited by this paper
• PPAR gamma is required for placental, cardiac, and adipose tissue development.

  1999cited by this paper
• Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

  1999cited by this paper
• Resistance to cisplatin.

  1999cited by this paper
• Loss-of-function mutations in PPAR gamma associated with human colon cancer.

  1999cited by this paper
• Differentiation and reversal of malignant changes in colon cancer through PPARγ

  1998cited by this paper
• Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice

  1998cited by this paper
• The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation.

  1998cited by this paper
• Cellular and molecular determinants of cisplatin resistance.

  1998cited by this paper
• Activators of the nuclear receptor PPARgamma enhance colon polyp formation.

  1998cited by this paper
• N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.

  1998cited by this paper
• Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.

  1997cited by this paper
• Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in esophageal cancer.

  1997cited by this paper
• PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A.

  1997cited by this paper
• 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma.

  1995cited by this paper
• An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).

  1995cited by this paper
• Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair.

  1994cited by this paper
• Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor.

  1994cited by this paper
• Cancer of the ovary.

  1993cited by this paper
• Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin.

  1991cited by this paper
• Expression and purification of the leucine zipper and DNA-binding domains of Fos and Jun: both Fos and Jun contact DNA directly.

  1990cited by this paper
• Overexpression of metallothionein confers resistance to anticancer drugs.

  1988cited by this paper
• Activation of transcription by two factors that bind promoter and enhancer sequences of the human metallothionein gene and SV40

  1987cited by this paper

• A New Era for PPARγ: Covalent Ligands and Therapeutic Applications.

  2025cites this paper
• Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning

  2025cites this paper
• Role of 4-Thiazolidinone–Pyrazoline/Indoline Hybrids Les-4369 and Les-3467 in BJ and A549 Cell Lines

  2024cites this paper
• PPARγ activation modulates the balance of peritoneal macrophage populations to suppress ovarian tumor growth and tumor-induced immunosuppression

  2023cites this paper
• Associations between body mass index, weight loss and overall survival in patients with advanced lung cancer

  2022cites this paper
• The Role of PPARs in Breast Cancer

  2022cites this paper
• Jiawei Yanghe Decoction Regulates Bone-Lipid Balance through the BMP-SMAD Signaling Pathway to Promote Osteogenic Differentiation of Bone Mesenchymal Stem Cells

  2022cites this paper
• Phenotypic plasticity during metastatic colonization.

  2022cites this paper
• Metabolomics-based phenotypic screens for evaluation of drug synergy via direct-infusion mass spectrometry

  2022cites this paper
• Antiproliferative, Antiangiogenic, and Antimetastatic Therapy Response by Mangiferin in a Syngeneic Immunocompetent Colorectal Cancer Mouse Model Involves Changes in Mitochondrial Energy Metabolism

  2021cites this paper
• DOCK4 Is a Platinum-Chemosensitive and Prognostic-Related Biomarker in Ovarian Cancer

  2021cites this paper
• Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation

  2021cites this paper
• PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action

  2021cites this paper
• Epigenetic derepression converts PPARγ into a druggable target in triple-negative and endocrine-resistant breast cancers

  2021cites this paper
• DHA/EPA-Enriched Phosphatidylcholine Suppresses Tumor Growth and Metastasis via Activating Peroxisome Proliferator-Activated Receptor γ in Lewis Lung Cancer Mice.

  2021cites this paper
• Verminoside from Pseudolysimachion rotundum var. subintegrum sensitizes cisplatin-resistant cancer cells and suppresses metastatic growth of human breast cancer

  2020cites this paper
• CB13, a novel PPARγ ligand, overcomes radio-resistance via ROS generation and ER stress in human non-small cell lung cancer

  2020cites this paper
• Retinoids Augment Thiazolidinedione PPARγ Activation in Oral Cancer Cells

  2020cites this paper
• Targeting cancer cell metastasis by converting cancer cells into fat.

  2019cites this paper
• PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model

  2019cites this paper
• PPARγ Agonists in Combination Cancer Therapies.

  2019cites this paper
• Drug Combinatorial Therapies for Treatment of KRAS Mutated Lung Cancers.

  2019cites this paper
• The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism

  2019cites this paper
• PPARγ Interaction with UBR5/ATMIN Promotes DNA Repair to Maintain Endothelial Homeostasis.

  2019cites this paper
• Gain Fat-Lose Metastasis: Converting Invasive Breast Cancer Cells into Adipocytes Inhibits Cancer Metastasis.

  2019cites this paper
• Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma

  2018cites this paper
• The PPARγ agonist rosiglitazone sensitizes the BH3 mimetic (−)‐gossypol to induce apoptosis in cancer cells with high level of Bcl‐2

  2018cites this paper
• Natural helix 9 mutants of PPARγ differently affect its transcriptional activity

  2018cites this paper
• PPARγ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF

  2018cites this paper
• Understanding the Interactions of High-Mobility Group of Protein Domain B1 with DNA Adducts Generated by Platinum Anticancer Molecules Using In Silico Approaches

  2018cites this paper
• Noncanonical agonist PPARγ ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy

  2018cites this paper
• PPAR Agonists for the Prevention and Treatment of Lung Cancer

  2017cites this paper
• Cytotoxic effects of 15-deoxy-Δ12,14-prostaglandin J2 alone and in combination with dasatinib against uterine sarcoma in vitro

  2017cites this paper
• An insight into the complex roles of metallothioneins in malignant diseases with emphasis on (sub)isoforms/isoforms and epigenetics phenomena

  2017cites this paper
• Peroxisome Proliferator-Activated Receptors and their Ligands in Cancer Drug- Resistance: Opportunity or Challenge.

  2016cites this paper
• A germline predictive signature of response to platinum chemotherapy in esophageal cancer.

  2016cites this paper
• In vitro toxicity assessment of oral nanocarriers.

  2016cites this paper
• Endotrophin, a multifaceted player in metabolic dysregulation and cancer progression, is a predictive biomarker for the response to PPARγ agonist treatment

  2016cites this paper
• PPARγ as a Novel Therapeutic Target in Lung Cancer

  2016cites this paper
• Rosiglitazone elevates sensitization of drug-resistant oral epidermoid carcinoma cells to vincristine by G2/M-phase arrest, independent of PPAR-γ pathway.

  2016cites this paper
• Discovering Anti-platelet Drug Combinations with an Integrated Model of Activator-Inhibitor Relationships, Activator-Activator Synergies and Inhibitor-Inhibitor Synergies

  2015cites this paper
• Nuclear Receptor Expression and Function in Human Lung Cancer Pathogenesis

  2015cites this paper
• Loss of PTEN Facilitates Rosiglitazone-Mediated Enhancement of Platinum(IV) Complex LA-12-Induced Apoptosis in Colon Cancer Cells

  2015cites this paper
• MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells

  2015cites this paper
• Chemotherapy and Chemoprevention by Thiazolidinediones

  2015cites this paper
• Minireview: Familiar Faces in Unfamiliar Places: The Emerging Role of Nuclear Receptors in Lung Cancer.

  2015cites this paper
• Mechanisms of obesity in the development of breast cancer.

  2015cites this paper
• Phase I study of Efatutazone, an oral PPARγ agonist, in patients with metastatic solid tumors.

  2014cites this paper
• Ubiquitin-mediated NFκB degradation pathway

  2014cites this paper
• Synthetic polyglutamylation of dual-functional MTX ligands for enhanced combined cytotoxicity of poly(I:C) nanoplexes.

  2014cites this paper
• Obesity and cancer—mechanisms underlying tumour progression and recurrence

  2014cites this paper
• Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs.

  2014cites this paper
• Therapeutics , Targets , and Chemical Biology Small Molecule Agonists of PPAR-g Exert Therapeutic Effects in Esophageal Cancer

  2014cites this paper
• PPARγ E3 ubiquitin ligase regulates MUC1-C oncoprotein stability

  2014cites this paper
• Small molecule agonists of PPAR-γ exert therapeutic effects in esophageal cancer.

  2014cites this paper
• ANTI-INSULIN RESISTANCE TREATMENTS SUPPRESS HER2+ BREAST CANCER GROWTH VIA ALTERING METABOLISM

  2014cites this paper
• The combinatory effects of PPAR-γ agonist and survivin inhibition on the cancer stem-like phenotype and cell proliferation in bladder cancer cells.

  2014cites this paper
• Manganese Superoxide Dismutase Is a Promising Target for Enhancing Chemosensitivity of Basal-Like Breast Carcinoma

  2014cites this paper
• Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer

  2013cites this paper
• Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours

  2013influential citation
• Induction of peroxisome proliferator-activated receptor γ (PPARγ)-mediated gene expression by tomato (Solanum lycopersicum L.) extracts.

  2013cites this paper
• Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy.

  2013cites this paper
• Adipocytes: impact on tumor growth and potential sites for therapeutic intervention.

  2013cites this paper
• Body Mass Index and Its Association with Clinical Outcomes for Advanced Non–Small-Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Trials

  2013cites this paper
• The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention

  2012cites this paper
• NHE-1: a promising target for novel anti-cancer therapeutics.

  2012cites this paper
• Distinct Genes Related to Drug Response Identified in ER Positive and ER Negative Breast Cancer Cell Lines

  2012cites this paper
• Research Resource: Diagnostic and Therapeutic Potential of Nuclear Receptor Expression in Lung Cancer

  2012cites this paper
• Meta analysis of gene expression changes upon treatment of A549 cells with anti-cancer drugs to identify universal responses

  2012cites this paper
• The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination

  2012cites this paper
• PPAR gamma, bioactive lipids, and cancer progression.

  2012cites this paper
• PPARγ is an E3 ligase that induces the degradation of NFκB/p65

  2012cites this paper
• Molecular mechanisms of cancer development in obesity

  2011cites this paper
• Balance between MKK6 and MKK3 Mediates p38 MAPK Associated Resistance to Cisplatin in NSCLC

  2011cites this paper
• Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.

  2011cites this paper
• Combined treatment with the Cox-2 inhibitor niflumic acid and PPARγ ligand ciglitazone induces ER stress/caspase-8-mediated apoptosis in human lung cancer cells.

  2011cites this paper
• PGC1α promotes tumor growth by inducing gene expression programs supporting lipogenesis.

  2011influential citation
• Molecular cross-regulation between PPAR-γ and other signaling pathways: implications for lung cancer therapy.

  2011cites this paper
• Integrated genomics of ovarian xenograft tumor progression and chemotherapy response

  2011influential citation
• Tumor and Stem Cell Biology PGC 1 a Promotes Tumor Growth by Inducing Gene Expression Programs Supporting Lipogenesis

  2011cites this paper
• PPARγ is functionally expressed in clear cell renal cell carcinoma.

  2011cites this paper
• Synergistic Interactions between Heregulin and Peroxisome Proliferator-activated Receptor-γ (PPARγ) Agonist in Breast Cancer Cells*

  2011cites this paper
• Redox environment and its meaning for breast cancer cells fate.

  2011cites this paper
• Tissue- and site-specific effects of PPARγ activation and its role in chronic inflammation

  2011cites this paper
• Evaluation of an extractionless high-performance liquid chromatography-tandem mass spectrometry method for detection and quantitation of rosiglitazone in canine plasma.

  2011cites this paper
• [Peroxisome proliferator-activated receptors (PPAR). Antiproliferative properties].

  2011cites this paper
• Paracrine and endocrine effects of adipose tissue on cancer development and progression.

  2011cites this paper
• In vitro and in vivo therapeutic efficacy of the PPAR‐γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth

  2010cites this paper
• Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions.

  2010cites this paper
• Inhibition of tumor angiogenesis by oral etoposide.

  2010cites this paper
• Troglitazone suppresses telomerase activity independently of PPARγ in estrogen-receptor negative breast cancer cells

  2010cites this paper
• Nuclear Receptor Expression Defines a Set of Prognostic Biomarkers for Lung Cancer

  2010cites this paper
• Optimal anti-angiogenic (metronomic) and anti-tumor doses of etoposide on angiogenesis, primary tumor growth and metastasis were established alone and in combination therapy. Etoposide inhibited endothelial and tumor cell proliferation, decreased vascular endothelial growth factor (VEGF) produc- tio

  2010cites this paper
• Epigenetic Silencing of Peroxisome Proliferator-Activated Receptor γ Is a Biomarker for Colorectal Cancer Progression and Adverse Patients' Outcome

  2010cites this paper
• Anticancer actions of PPARγ ligands: Current state and future perspectives in human lung cancer.

  2010cites this paper
• Mistletoe lectin‐I augments antiproliferative effects of the PPARγ agonist rosiglitazone on human malignant melanoma cells

  2010cites this paper
• Blossom proliferative loops in PI 3 K / Akt / mTOR-addicted lymphomas Dual inhibition of PI 3 K and mTOR inhibits autocrine and paracrine

  2010cites this paper
• Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.

  2010cites this paper
• KLF4‐dependent, PPARγ‐induced expression of GPA33 in colon cancer cell lines

  2009cites this paper
• PPARG: a new independent marker for colorectal cancer survival.

  2009cites this paper